Literature DB >> 16490609

Increased efficiency in evaluating patients with suspected tuberculosis by use of a dedicated airborne infection isolation unit.

Michael K Leonard1, Kathleen B Egan, Ekaterina Kourbatova, Nancy White, Patricia Parrott, Carlos Del Rio, Henry M Blumberg.   

Abstract

BACKGROUND: The resurgence of tuberculosis (TB) in the 1980s and early 1990s in the United States was also accompanied by numerous hospital outbreaks of TB and nosocomial transmission to health care workers.
OBJECTIVE: To determine whether a dedicated airborne infection isolation (AII) unit improves efficiency in "ruling-out" patients suspected of having pulmonary TB. This is important because, to prevent nosocomial transmission of TB, the number and ratio of patients isolated who are subsequently found to have TB is much higher than those "ruled out" and have TB excluded.
METHODS: A prospective cohort study was conducted of all patients 18 years and older admitted to respiratory isolation during 3 separate time periods before and after opening of an 26-bed AII unit in a 1000-bed, public, university-affiliated, innercity hospital.
RESULTS: A total of 879 patients were admitted during the 3 study periods. Most were black and males (87%, 72%, respectively). The median age was 42 years, and 70% of patients included in the study were HIV positive. Among patients who "ruled out," ie, TB was excluded by having 3 negative AFB smears of respiratory specimens for TB, there was a significant decrease in time from 5.0 days in period I to 3.3 days in period III (P < .0001). In period III, patients who were admitted to rule out TB in areas outside of the AII unit in other wards of the hospital required a significantly longer period to have TB excluded: 5.9 days compared with 3.5 on the AII unit (P = .0015).
CONCLUSION: The decrease in isolation time after the opening of the dedicated AII unit demonstrates that a concerted effort to rule patients out by having nurses and respiratory therapists trained in tuberculosis control is efficacious and efficient and results in significant cost savings.

Entities:  

Mesh:

Year:  2006        PMID: 16490609     DOI: 10.1016/j.ajic.2005.09.003

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  6 in total

1.  Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States.

Authors:  Christopher K Lippincott; Melissa B Miller; Elena B Popowitch; Colleen F Hanrahan; Annelies Van Rie
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

2.  A national infection control evaluation of drug-resistant tuberculosis hospitals in South Africa.

Authors:  J E Farley; C Tudor; M Mphahlele; K Franz; N A Perrin; S Dorman; M Van der Walt
Journal:  Int J Tuberc Lung Dis       Date:  2012-01       Impact factor: 2.373

3.  Diagnosis of tuberculosis by using a nucleic acid amplification test in an urban population with high HIV prevalence in the United States.

Authors:  Miwako Kobayashi; Susan M Ray; John Hanfelt; Yun F Wang
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

4.  Clinical Impact of Nucleic Acid Amplification Testing in the Diagnosis of Mycobacterium Tuberculosis: A 10-Year Longitudinal Study.

Authors:  Kassem Bourgi; Jaimin Patel; Linoj Samuel; Angela Kieca; Laura Johnson; George Alangaden
Journal:  Open Forum Infect Dis       Date:  2017-03-10       Impact factor: 3.835

5.  Cost analysis of a nucleic acid amplification test in the diagnosis of pulmonary tuberculosis at an urban hospital with a high prevalence of TB/HIV.

Authors:  Max W Adelman; Ekaterina Kurbatova; Yun F Wang; Michael K Leonard; Nancy White; Deborah A McFarland; Henry M Blumberg
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

6.  Impact of Infection Control Measures to Control an Outbreak of Multidrug-Resistant Tuberculosis in a Human Immunodeficiency Virus Ward, Peru.

Authors:  Eduardo Ticona; Luz Huaroto; Daniela E Kirwan; Milagros Chumpitaz; César V Munayco; Mónica Maguiña; Marco A Tovar; Carlton A Evans; Roderick Escombe; Robert H Gilman
Journal:  Am J Trop Med Hyg       Date:  2016-09-12       Impact factor: 2.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.